Commentary: preclinical efficacy of immune-checkpoint monotherapy does not recapitulate corresponding biomarkers-based clinical predictions in glioblastoma by Garg et al. (2017)

Lijie Zhai, Erik Ladomersky, Kristen L. Lauing, Meijing Wu, Denise M. Scholtens, Rohan Savoor, Bin Zhang, Jennifer D. Wu, Craig Horbinski, Rimas V. Lukas, David C. Binder, Derek A. Wainwright*

*Corresponding author for this work

Research output: Contribution to journalComment/debate


Preclinical modeling and gene expression analyses have yielded distinct observations for the role of immune checkpoint, IDO1, in glioblastoma (GBM). Accordingly, our recent work differs with Garg et al. (2017) with respect to IDO1 among preclinical and bioinformatic GBM datasets. Here, we discuss the methodological differences that affected study interpretation, and potentially, future clinical decision-making for IDO1-targeting approaches against GBM.

Original languageEnglish (US)
Article number1548242
Issue number3
StatePublished - Mar 4 2019



  • IDO
  • Treg
  • brain tumor
  • glioblastoma
  • immunosuppression
  • immunotherapy

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology

Cite this